"Imatinib Mesylate as Add-On Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study"
Circ Feb 12, 2013
http://circ.ahajournals.org/content/early/2013/02/12/CIRCULATIONAHA.112.000765.abstract
"Conclusions—Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH but serious adverse events and study drug discontinuations were common. Further studies are needed to investigate the long-term safety and efficacy of imatinib in patients with PAH."